Literature DB >> 7541237

Immunohistochemical expression of tenascin in normal stomach tissue, gastric carcinomas and gastric carcinoma in lymph nodes.

Y Ikeda1, M Mori, K Kajiyama, Y Haraguchi, O Sasaki, K Sugimachi.   

Abstract

The immunohistochemical expression of tenascin was examined in the normal adult mucosa of the stomach, primary tumours and lymph node metastases of gastric cancer patients. In normal gastric tissue tenascin was expressed in the muscularis mucosae, muscularis propria and vessel walls, however it was not expressed in either the mucosal connective tissue or the stromal tissue in the submucosal layer. In gastric cancer, tenascin was expressed in 35 of 85 primary tumours, and in 8 of 25 metastases in lymph nodes. Tenascin was located in the fibrous stroma surrounding foci of cancer. The expression of tenascin in the primary tumour did not correlate with the depth of invasion, lymph node metastasis or prognosis. Tenascin appears during the process of either malignant transformation or tumour progression in gastric cancer, and the positive expression of tenascin may be useful as a stromal marker for the early detection of gastric cancer.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7541237      PMCID: PMC2034161          DOI: 10.1038/bjc.1995.301

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  26 in total

1.  Gastric carcinoma. A pathobiological classification.

Authors:  S C Ming
Journal:  Cancer       Date:  1977-06       Impact factor: 6.860

2.  Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis.

Authors:  R Chiquet-Ehrismann; E J Mackie; C A Pearson; T Sakakura
Journal:  Cell       Date:  1986-10-10       Impact factor: 41.582

3.  Tenascin is a stromal marker for epithelial malignancy in the mammary gland.

Authors:  E J Mackie; R Chiquet-Ehrismann; C A Pearson; Y Inaguma; K Taya; Y Kawarada; T Sakakura
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

Review 4.  Tenascin: an extracellular matrix protein prominent in specialized embryonic tissues and tumors.

Authors:  H P Erickson; M A Bourdon
Journal:  Annu Rev Cell Biol       Date:  1989

5.  Carcinoma of the stomach in incipient phase: its histogenesis and histological appearances.

Authors:  K Nakamura; H Sugano; K Takagi
Journal:  Gan       Date:  1968-06

Review 6.  What distinguishes tenascin from fibronectin?

Authors:  R Chiquet-Ehrismann
Journal:  FASEB J       Date:  1990-06       Impact factor: 5.191

7.  Tenascin immunoreactivity in lung tumors.

Authors:  Y Soini; P Pääkkö; K Nuorva; D Kamel; A Linnala; I Virtanen; V P Lehto
Journal:  Am J Clin Pathol       Date:  1993-08       Impact factor: 2.493

Review 8.  Pathological studies of human gastric cancer.

Authors:  H Sugano; K Nakamura; Y Kato
Journal:  Acta Pathol Jpn       Date:  1982

9.  Tenascin during gut development: appearance in the mesenchyme, shift in molecular forms, and dependence on epithelial-mesenchymal interactions.

Authors:  E Aufderheide; P Ekblom
Journal:  J Cell Biol       Date:  1988-12       Impact factor: 10.539

10.  Chick myotendinous antigen. I. A monoclonal antibody as a marker for tendon and muscle morphogenesis.

Authors:  M Chiquet; D M Fambrough
Journal:  J Cell Biol       Date:  1984-06       Impact factor: 10.539

View more
  6 in total

1.  Tenascin immunoreactivity in the large bowel and the liver in patients with colorectal cancer.

Authors:  M V Gulubova; T Vlaykova
Journal:  Histochem J       Date:  2001-02

2.  Laminins, tenascin and type VII collagen in colorectal mucosa.

Authors:  J Lohi; I Leivo; T Tani; T Kiviluoto; E Kivilaakso; R E Burgeson; I Virtanen
Journal:  Histochem J       Date:  1996-06

3.  Stromal tenascin distribution as a prognostic marker in colorectal cancer.

Authors:  U Kressner; G Lindmark; B Tomasini-Johansson; R Bergström; B Gerdin; L Påhlman; B Glimelius
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

4.  Tenascin and oncofetal fibronectin--oncofetal markers or indicators of extracellular matrix remodelling?

Authors:  L David
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

Review 5.  T-Cell Immunotherapy for Pediatric High-Grade Gliomas: New Insights to Overcoming Therapeutic Challenges.

Authors:  Dalia Haydar; Jorge Ibañez-Vega; Giedre Krenciute
Journal:  Front Oncol       Date:  2021-10-25       Impact factor: 6.244

Review 6.  Tenascin-C: Form versus function.

Authors:  Sean P Giblin; Kim S Midwood
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.